The Cooper Companies, Inc. (COO)
Pre-market:
| Previous close | 416.13 |
| Open | 414.85 |
| Bid | 0.00 x 800 |
| Ask | 0.00 x 900 |
| Day's range | 404.63 - 416.40 |
| 52-week range | 359.84 - 463.59 |
| Volume | |
| Avg. volume | 314,037 |
| Market cap | 20.283B |
| Beta (5Y monthly) | 0.88 |
| PE ratio (TTM) | 6.94 |
| EPS (TTM) | 59.16 |
| Earnings date | 02 Mar 2022 - 07 Mar 2022 |
| Forward dividend & yield | 0.06 (0.01%) |
| Ex-dividend date | 20 Jan 2022 |
| 1y target est | 470.46 |
- GlobeNewswire
CooperCompanies to Present at the J.P. Morgan Healthcare Conference
SAN RAMON, Calif., Jan. 06, 2022 (GLOBE NEWSWIRE) -- CooperCompanies (NYSE: COO), will present at the J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022. Al White, President and CEO, will represent the Company in a virtual session scheduled to begin at 2:15 PM ET. A live webcast of the presentation will be available to all interested parties on the Investor Relations section of CooperCompanies’ website at http://investor.coopercos.com. The webcast will be available for 30 days follow
- Zacks
HSIC vs. COO: Which Stock Should Value Investors Buy Now?
HSIC vs. COO: Which Stock Is the Better Value Option?
- GlobeNewswire
CooperCompanies Completes Acquisition of Generate Life Sciences®
SAN RAMON, Calif., Dec. 17, 2021 (GLOBE NEWSWIRE) -- CooperCompanies (NYSE: COO) today announced it has completed the previously announced definitive purchase agreement to acquire Generate Life Sciences, a leading provider of donor egg and sperm for fertility treatments, fertility cryopreservation services and newborn stem cell storage (cord blood & cord tissue), for a purchase price of approximately $1.6 billion. “We are excited to complete this transaction and welcome the Generate employees to
